Compare FGI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FGI | PRPO |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 32.4M |
| IPO Year | 2022 | N/A |
| Metric | FGI | PRPO |
|---|---|---|
| Price | $5.74 | $22.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 75.1K | 7.2K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $135,654,095.00 | $22,800,000.00 |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.66 | ★ 30.95 |
| 52 Week Low | $2.28 | $3.90 |
| 52 Week High | $12.62 | $28.50 |
| Indicator | FGI | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 47.31 |
| Support Level | $5.51 | $22.40 |
| Resistance Level | $6.10 | $24.92 |
| Average True Range (ATR) | 0.64 | 1.29 |
| MACD | -0.15 | -0.17 |
| Stochastic Oscillator | 19.90 | 30.04 |
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.